Maen Hussein

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
INTRODUCTION Therapeutic antibodies to immune checkpoints show promising results. Programmed death-ligand 1 (PD-L1), an immune checkpoint ligand, blocks the cancer immunity cycle by binding the PD-L1 receptor (programmed death 1). We investigated PD-L1 protein expression and messenger RNA (mRNA) levels in SCLC. METHODS PD-L1 protein expression and mRNA(More)
Background The majority of lung cancer in the U.S. is treated in the community. A prospective cohort study of stage IV NSCLC and extensive disease (ED) SCLC is being conducted in 70 U.S. community practices to assess outcomes during the preand post-immunotherapy eras of lung cancer treatment. This analysis focuses on characteristics of the rarer SCLC subset(More)
Maen Hussein, MD, and Rami Y. Haddad, MD, FACP nemia is one of the most common blood diseases. The number of visits o physician offices, hospital outpatient and emergency departments with nemia as primary diagnosis was 5.5 million in the year 2005-2006. ineteen percent of nursing home residents are diagnosed with anemia. he World Health Organization(More)
  • 1